|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
PT1482932E
(pt)
*
|
2002-03-13 |
2010-01-12 |
Array Biopharma Inc |
Derivados de benzimidazole alquilado n3 como inibidores de mek
|
|
US20060084682A1
(en)
*
|
2002-12-13 |
2006-04-20 |
Heerding Dirk A |
Thrombopoietin mimetics
|
|
EP1598079B1
(en)
*
|
2003-02-26 |
2009-04-22 |
Kowa Co., Ltd. |
Remedies for allergic contact dermatitis
|
|
ES2331246T3
(es)
|
2003-07-24 |
2009-12-28 |
Warner-Lambert Company Llc |
Derivados de benzamidazol como inhibidores del mek.
|
|
US7538120B2
(en)
*
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
TWI349664B
(en)
*
|
2003-09-22 |
2011-10-01 |
S Bio Pte Ltd |
Benzimidazole derivatives: preparation and pharmaceutical applications
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
KR101190912B1
(ko)
*
|
2003-11-19 |
2012-10-12 |
어레이 바이오파마 인크. |
Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
|
|
BRPI0416852A
(pt)
*
|
2003-11-21 |
2007-02-27 |
Array Biopharma Inc |
inibidores da quinase akt
|
|
JP2007513967A
(ja)
*
|
2003-12-11 |
2007-05-31 |
セラヴァンス， インコーポレーテッド |
変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
|
|
SI1802579T1
(sl)
|
2004-10-20 |
2014-03-31 |
Merck Serono Sa |
Derivati 3-arilaminopiridina
|
|
AU2005311451A1
(en)
*
|
2004-12-01 |
2006-06-08 |
Merck Serono Sa |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
|
US7429667B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
CN102321030A
(zh)
|
2005-05-18 |
2012-01-18 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
AU2006262375A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Array Biopharma Inc. |
SNAr process for preparing benzimidazole compounds
|
|
ES2567133T3
(es)
*
|
2005-06-23 |
2016-04-20 |
Array Biopharma, Inc. |
Proceso para preparar compuestos de benzoimidazol
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
AU2006302415B2
(en)
|
2005-10-07 |
2012-09-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
US7968108B2
(en)
*
|
2005-10-25 |
2011-06-28 |
Metbro Distributing L.P. |
Hydrogen cyanamide pesticide formulations
|
|
US7572460B2
(en)
*
|
2005-10-25 |
2009-08-11 |
Rodrigo Rodriguez-Kabana |
Hydrogen cyanamide pesticide formulations
|
|
RU2418790C3
(ru)
*
|
2005-12-21 |
2022-03-14 |
Астразенека Аб |
Новая гидросульфатная соль
|
|
EP1966155A1
(en)
*
|
2005-12-21 |
2008-09-10 |
AstraZeneca AB |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
CA2534243A1
(fr)
|
2006-01-25 |
2007-07-25 |
Hydro Quebec |
Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
EP2012786B1
(en)
*
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
|
DK2054418T3
(da)
|
2006-07-06 |
2012-02-27 |
Array Biopharma Inc |
Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
SI2049500T1
(sl)
|
2006-07-06 |
2012-01-31 |
Array Biopharma Inc |
Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
KR101475088B1
(ko)
|
2006-08-21 |
2014-12-23 |
제넨테크, 인크. |
아자-벤조티오페닐 화합물 및 사용 방법
|
|
KR101428116B1
(ko)
*
|
2006-08-21 |
2014-08-07 |
제넨테크, 인크. |
아자-벤조푸라닐 화합물 및 사용 방법
|
|
CN101583616B
(zh)
*
|
2006-08-21 |
2012-05-30 |
健泰科生物技术公司 |
氮杂苯并噻吩基化合物及使用方法
|
|
CN105106199A
(zh)
|
2006-12-14 |
2015-12-02 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
US20100130519A1
(en)
*
|
2007-04-13 |
2010-05-27 |
Stephen Robert Wedge |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換アザインドール類及び使用方法
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
EP2170863B1
(en)
|
2007-07-05 |
2015-09-02 |
Array Biopharma, Inc. |
Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases
|
|
ATE522509T1
(de)
|
2007-07-05 |
2011-09-15 |
Array Biopharma Inc |
Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
RU2010118452A
(ru)
*
|
2007-10-15 |
2011-11-27 |
Астразенека Аб (Se) |
Комбинация 059
|
|
ES2456966T3
(es)
|
2007-11-12 |
2014-04-24 |
Takeda Pharmaceutical Company Limited |
Inhibidores de MAPK/ERK cinasa
|
|
CA2704125A1
(en)
|
2007-12-19 |
2009-07-09 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
PT2690101E
(pt)
|
2007-12-19 |
2015-10-08 |
Genentech Inc |
5-anilinoimidazopiridinas e métodos de utilização
|
|
BRPI0820696A2
(pt)
|
2007-12-20 |
2019-09-24 |
Hoffmann La Roche |
hidantoínas substituídas como inibidores de cinase de mek
|
|
ES2387707T3
(es)
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
|
CN101932565B
(zh)
*
|
2008-01-09 |
2013-06-12 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷
|
|
CA2711699A1
(en)
|
2008-01-09 |
2009-07-16 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
JP5404622B2
(ja)
|
2008-06-23 |
2014-02-05 |
パナソニック株式会社 |
無線通信基地局装置および参照信号割当方法
|
|
MX2010014559A
(es)
|
2008-07-01 |
2011-03-04 |
Genentech Inc |
Heterociclos bicíclicos sustituidos y metodos de uso.
|
|
CN102137843A
(zh)
*
|
2008-07-01 |
2011-07-27 |
健泰科生物技术公司 |
作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
|
|
WO2010017051A1
(en)
|
2008-08-04 |
2010-02-11 |
Merck Serono S.A. |
Novel phenylamino isonicotinamide compounds
|
|
CN101653607B
(zh)
*
|
2008-08-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
|
|
WO2010051245A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Benzimidazole and aza-benzimidazole carboxamides
|
|
JP5746630B2
(ja)
|
2008-11-10 |
2015-07-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換スルホンアミドフェノキシベンズアミド
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
EP2491016A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
CA2777304A1
(en)
|
2009-10-21 |
2011-04-28 |
Marion Hitchcock |
Substituted benzosulphonamides
|
|
WO2011047796A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
|
CA2803055A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
WO2012019113A2
(en)
|
2010-08-05 |
2012-02-09 |
Case Western Reserve University |
Inhibitors of erk for developmental disorders of neuronal connectivity
|
|
SI2624696T1
(sl)
|
2010-10-06 |
2017-04-26 |
Glaxosmithkline Llc Corporation Service Company |
Benzimidazolni derivati kot inhibitorji pi3-kinaze
|
|
JP2013542214A
(ja)
|
2010-10-29 |
2013-11-21 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
置換フェノキシピリジン類
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
|
ES2531465T3
(es)
|
2010-12-23 |
2015-03-16 |
Sanofi |
Derivados de pirimidinona, su preparación y su utilización farmacéutica
|
|
CN103857395A
(zh)
|
2011-04-01 |
2014-06-11 |
基因泰克公司 |
Akt抑制剂化合物和阿比特龙的组合及使用方法
|
|
US9682082B2
(en)
|
2011-04-01 |
2017-06-20 |
Genentech, Inc. |
Combinations of AKT and MEK inhibitor compounds, and methods of use
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
US20140228418A1
(en)
*
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
TW202114735A
(zh)
|
2011-08-01 |
2021-04-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
US10314594B2
(en)
|
2012-12-14 |
2019-06-11 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US10813630B2
(en)
|
2011-08-09 |
2020-10-27 |
Corquest Medical, Inc. |
Closure system for atrial wall
|
|
US10307167B2
(en)
|
2012-12-14 |
2019-06-04 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US9675595B2
(en)
|
2011-08-31 |
2017-06-13 |
Novartis Ag |
Synergistic combinations of PI3K- and MEK-inhibitors
|
|
US9034909B2
(en)
*
|
2011-09-01 |
2015-05-19 |
Novartis Ag |
Use of organic compound for the treatment of Noonan Syndrome
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
JP2014530243A
(ja)
|
2011-10-14 |
2014-11-17 |
アレイ バイオファーマ、インコーポレイテッド |
Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
|
|
AU2012332421A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
|
|
US20140286902A1
(en)
|
2011-11-02 |
2014-09-25 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
WO2013105022A2
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
WO2013142182A2
(en)
|
2012-03-20 |
2013-09-26 |
Novartis Pharma Ag |
Combination therapy
|
|
US10054835B2
(en)
|
2012-04-09 |
2018-08-21 |
Switch Materials, Inc. |
Switching materials, and compositions and methods for making same
|
|
CN104508520B
(zh)
|
2012-05-29 |
2018-03-27 |
思维奇材料公司 |
包含可变透射率层的滤光片
|
|
KR20150013332A
(ko)
|
2012-05-31 |
2015-02-04 |
바이엘 파마 악티엔게젤샤프트 |
간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
CA2879252C
(en)
|
2012-08-17 |
2017-10-10 |
F. Hoffmann-La Roche Ag |
Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
|
|
HUE033380T2
(en)
|
2012-10-02 |
2017-11-28 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
|
AU2013328929B2
(en)
|
2012-10-12 |
2018-01-04 |
Exelixis, Inc. |
Novel process for making compounds for use in the treatment of cancer
|
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
|
PT3702351T
(pt)
*
|
2012-10-19 |
2024-01-17 |
Array Biopharma Inc |
Formulação contendo um inibidor de mek
|
|
US20140142689A1
(en)
|
2012-11-21 |
2014-05-22 |
Didier De Canniere |
Device and method of treating heart valve malfunction
|
|
CN104812415A
(zh)
*
|
2012-11-29 |
2015-07-29 |
诺华股份有限公司 |
药物组合
|
|
EP2934515B1
(en)
|
2012-12-20 |
2018-04-04 |
Novartis AG |
A pharmaceutical combination comprising binimetinib
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
|
MX2015011097A
(es)
|
2013-02-27 |
2016-03-09 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas.
|
|
EP2963114B1
(en)
|
2013-02-27 |
2018-12-12 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
MA44934B1
(fr)
*
|
2013-03-21 |
2021-11-30 |
Novartis Ag |
Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur
|
|
AR097617A1
(es)
|
2013-09-13 |
2016-04-06 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos del 2h-indazol
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9566443B2
(en)
|
2013-11-26 |
2017-02-14 |
Corquest Medical, Inc. |
System for treating heart valve malfunction including mitral regurgitation
|
|
PL3083567T3
(pl)
|
2013-12-19 |
2018-08-31 |
Idorsia Pharmaceuticals Ltd |
Przeciwbakteryjne pochodne 1h-indazolu i 1h-indolu
|
|
US20160340407A1
(en)
|
2014-01-14 |
2016-11-24 |
Dana-Farber Camcer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
AR099612A1
(es)
|
2014-03-04 |
2016-08-03 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
|
|
CN106414721A
(zh)
|
2014-03-04 |
2017-02-15 |
菲特治疗公司 |
改良的重编程方法和细胞培养平台
|
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CA2943824A1
(en)
|
2014-03-31 |
2015-10-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
SG11201609286VA
(en)
|
2014-05-16 |
2016-12-29 |
Actelion Pharmaceuticals Ltd |
Antibacterial quinazoline-4(3h)-one derivatives
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
RU2733735C2
(ru)
|
2014-07-15 |
2020-10-06 |
Дженентек, Инк. |
Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek
|
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
|
AU2015314756A1
(en)
|
2014-09-13 |
2017-03-16 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
US10842626B2
(en)
|
2014-12-09 |
2020-11-24 |
Didier De Canniere |
Intracardiac device to correct mitral regurgitation
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
SG11201703880VA
(en)
|
2014-12-23 |
2017-07-28 |
Novartis Ag |
Triazolopyrimidine compounds and uses thereof
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN105566225A
(zh)
*
|
2015-02-16 |
2016-05-11 |
苏州晶云药物科技有限公司 |
一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
CN107667092B
(zh)
|
2015-03-25 |
2021-05-28 |
诺华股份有限公司 |
作为fgfr4抑制剂的甲酰化n-杂环衍生物
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
AR105646A1
(es)
|
2015-08-11 |
2017-10-25 |
Actelion Pharmaceuticals Ltd |
Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
EP3340989B1
(en)
|
2015-08-28 |
2023-08-16 |
Novartis AG |
Mdm2 inhibitors and combinations thereof
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
HUE057837T2
(hu)
|
2015-11-03 |
2022-06-28 |
Janssen Biotech Inc |
PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7085985B2
(ja)
|
2016-03-04 |
2022-06-17 |
大鵬薬品工業株式会社 |
悪性腫瘍治療用製剤及び組成物
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
PT3463345T
(pt)
|
2016-06-03 |
2023-01-06 |
Array Biopharma Inc |
Combinações farmacêuticas
|
|
ES2975263T3
(es)
|
2016-06-20 |
2024-07-04 |
Novartis Ag |
Formas cristalinas de un compuesto triazolopirimidínico
|
|
CN109790166A
(zh)
|
2016-06-20 |
2019-05-21 |
诺华股份有限公司 |
咪唑并吡啶化合物用于治疗癌症
|
|
ES2798424T3
(es)
|
2016-06-20 |
2020-12-11 |
Novartis Ag |
Compuestos de triazolopiridina y usos de estos
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018065924A1
(en)
*
|
2016-10-04 |
2018-04-12 |
Sun Pharmaceutical Industries Limited |
Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CN108084078B
(zh)
*
|
2016-11-24 |
2021-07-30 |
中山大学 |
一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
|
|
EP3548049A4
(en)
|
2016-12-05 |
2020-07-22 |
Fate Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
|
|
EP3372624A1
(en)
|
2017-03-06 |
2018-09-12 |
Henkel AG & Co. KGaA |
One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN111646946A
(zh)
*
|
2017-11-14 |
2020-09-11 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
MY203305A
(en)
|
2018-03-19 |
2024-06-23 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
MX2020010437A
(es)
|
2018-04-05 |
2021-01-29 |
Sumitomo Pharma Oncology Inc |
Inhibidores de axl cinasa y uso de los mismos.
|
|
US11746157B2
(en)
|
2018-05-24 |
2023-09-05 |
Janssen Biotech, Inc. |
PSMA binding agents and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
EP4545101B1
(en)
|
2018-07-25 |
2025-12-10 |
Advanced Accelerator Applications S.A. |
Stable, concentrated radionuclide complex solutions
|
|
EP3826684A4
(en)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
|
|
PT3837256T
(pt)
|
2018-08-17 |
2023-05-23 |
Novartis Ag |
Compostos e composições de ureia como inibidores de smarca2/brm-atpase
|
|
US20210346527A1
(en)
|
2018-09-25 |
2021-11-11 |
Advanced Accelerator Applications (Italy) Srl |
Combination Therapy
|
|
US12378240B2
(en)
|
2018-11-20 |
2025-08-05 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
JP7406264B2
(ja)
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのシアノアリール－アニリン化合物
|
|
CN117551073A
(zh)
|
2018-11-20 |
2024-02-13 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病噻吩基苯胺化合物
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN114364798A
(zh)
|
2019-03-21 |
2022-04-15 |
欧恩科斯欧公司 |
用于治疗癌症的Dbait分子与激酶抑制剂的组合
|
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
|
|
WO2020212832A1
(en)
*
|
2019-04-16 |
2020-10-22 |
Alembic Pharmaceuticals Limited |
Process of preparation of benzimidazole compounds
|
|
WO2020212947A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
US20220280509A1
(en)
|
2019-09-26 |
2022-09-08 |
Novartis Ag |
Aza-quinoline compounds and uses thereof
|
|
US20220401436A1
(en)
|
2019-11-08 |
2022-12-22 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021116901A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Biocon Limited |
Forms of binimetinib and process for preparation thereof
|
|
IL293834A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
JP2023517393A
(ja)
*
|
2020-03-17 |
2023-04-25 |
メッドシャイン ディスカバリー インコーポレイテッド |
タンパク質分解調整剤およびその使用方法
|
|
US20230165862A1
(en)
|
2020-04-10 |
2023-06-01 |
Taiho Pharmaceutical Co., Ltd. |
Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
|
|
JP7312335B2
(ja)
|
2020-06-09 |
2023-07-20 |
アレイ バイオファーマ インコーポレイテッド |
Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022074011A1
(en)
|
2020-10-05 |
2022-04-14 |
Pierre Fabre Medicament |
Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN112679438A
(zh)
*
|
2020-12-31 |
2021-04-20 |
武汉九州钰民医药科技有限公司 |
制备司美替尼的方法
|
|
CN112759552A
(zh)
*
|
2020-12-31 |
2021-05-07 |
武汉九州钰民医药科技有限公司 |
司美替尼的合成方法
|
|
US12141240B2
(en)
|
2021-01-20 |
2024-11-12 |
Rutgers, The State University Of New Jersey |
Method of calibration using master calibration function
|
|
CA3205523A1
(en)
*
|
2021-01-21 |
2022-07-28 |
Michael Houghton |
Processes for preparing pyrrolopyridine-aniline compounds
|
|
JP2024504758A
(ja)
|
2021-01-28 |
2024-02-01 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ結合タンパク質及びその使用
|
|
CN117794929A
(zh)
|
2021-02-02 |
2024-03-29 |
法国施维雅药厂 |
选择性bcl-xl protac化合物及使用方法
|
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
US20240207257A1
(en)
*
|
2021-04-15 |
2024-06-27 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a pkc inhibitor and a mek inhibitor
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4346826A4
(en)
|
2021-05-27 |
2025-04-30 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
EP4351577A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination therapy for cancer treatment
|
|
WO2022262699A1
(zh)
*
|
2021-06-17 |
2022-12-22 |
深圳市塔吉瑞生物医药有限公司 |
取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
|
|
KR20240035820A
(ko)
|
2021-07-09 |
2024-03-18 |
플렉시움 인코포레이티드 |
Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
|
|
KR20240105382A
(ko)
|
2021-11-04 |
2024-07-05 |
에프. 호프만-라 로슈 아게 |
암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
|
|
WO2023084489A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
CA3255993A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
BCL-XL ANTIBODY-DRUG CONJUGATES AND ASSOCIATED METHODS OF USE
|
|
CA3256012A1
(en)
|
2022-05-20 |
2023-11-23 |
Les Laboratoires Servier |
ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
|
|
US20250340518A1
(en)
*
|
2022-06-06 |
2025-11-06 |
Glenmark Life Sciences Limited |
Process for preparation of selumetinib and salts thereof
|
|
WO2024105144A1
(en)
|
2022-11-18 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
|
|
WO2024189481A1
(en)
|
2023-03-10 |
2024-09-19 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN120813358A
(zh)
|
2023-04-06 |
2025-10-17 |
卫材R&D管理有限公司 |
用于治疗肿瘤的药物组合物
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
FR3159741A1
(fr)
|
2024-03-04 |
2025-09-05 |
Pierre Fabre Medicament |
Formulation topique comprenant du binimetinib
|
|
TW202539634A
(zh)
|
2024-04-10 |
2025-10-16 |
瑞士商諾華公司 |
Ｐａｎｒａｓ抑制劑及其使用方法
|
|
PL451049A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451048A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451046A1
(pl)
*
|
2025-01-27 |
2025-06-09 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL248506B1
(pl)
*
|
2025-01-27 |
2025-12-22 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451050A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451047A1
(pl)
*
|
2025-01-27 |
2025-08-18 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|